Ioana Parsons

Acumen Pharmaceuticals

James Doherty

Acumen Pharmaceuticals has appointed James Doherty as president and chief development officer. Doherty brings decades of neuroscience-focused research and clinical development expertise to his new position. He most recently served as chief development officer at SAGE Therapeutics and previously held the position of director, neuroscience for over a decade at AstraZeneca.

Resalis Therapeutics

Almut Nitsche

Resalis Therapeutics has appointed Almut Nitsche as chief medical and development officer. Nitsche brings over two decades of experience in the pharmaceutical industry to her new position. She most recently served as consultant to Proxidrugs. Prior to this, Nitsche held a variety of roles at Sanofi, most recently as project director, early development.

NodThera

Thomas Jaecklin

NodThera has appointed Thomas Jaecklin as chief medical officer. Jaecklin brings over two decades of experience across global pharma, biotech and academic medicine to his new role. He most recently served as vice president and global programme head at Galapagos. Prior to this, Jaecklin also held leadership roles at Mirum Pharmaceuticals and Shire.

GRO Biosciences

Tracey Lodie

GRO Biosciences has appointed Tracey Lodie as chief development officer. Lodie brings over two decades of experience in the biopharmaceutical industry to her new position. She most recently served as chief scientific officer at Quell Therapeutics. Prior to this, Lodie was chief scientific officer at Gamida Cell and held senior positions at Blue Rock Therapeutics and Sanofi/Genzyme.

GSK

Jeannie Lee

GSK has appointed Jeannie Lee to its board as non-executive director. Lee carries a wealth of experience and expertise in scientific and medical innovation. She currently serves as the Phillip A Sharp, endowed chair in molecular biology and acting chair of molecular biology at the Massachusetts General Hospital and professor of genetics at Harvard Medical School.

Owkin

Jean-Jacques Bienaimé

Owkin has appointed Jean-Jacques Bienaimé as chairman of the board. Bienaimé brings over three decades of pharmaceutical experience to his new role. He was most recently chief executive officer at BioMarin Pharmaceuticals. In addition, he also serves on the board for multiple company’s including Incyte, Vital Therapies and more recently PhRMA Foundation.

Asceneuron

Samantha Budd-Haeberlein

Asceneuron has appointed Samantha Budd-Haeberlein to its scientific advisory board. Budd-Haeberlein possesses a wealth of expertise in neurodegenerative diseases. She is currently chief medical officer at Enigma Biomedical Group and senior advisor for ICG Life Sciences. Prior to this, Budd-Haeberlein was senior vice president and head of neurodegeneration, Europe at Biogen.

iTeos Therapeutics

Jill DeSimone

iTeos Therapeutics has appointed Jill DeSimone to its board of directors. DeSimone holds over four decades of experience in global business in life sciences. She currently serves as a board member for several companies including Kinnate Biopharma and Oncternal Therapeutics. Prior to this, she served as president of US oncology at Merck & Co.